
Pairing semaglutide, a drug used to treat diabetes, with a minimally invasive endoscopic sleeve gastroplasty (ESG) can provide significant weight loss benefits for patients who are not candidates for invasive weight loss surgery, according to a study presented at Digestive Disease Week 2021.




























